Showing 8041-8050 of 10737 results for "".
Connective Tissue Disorders Update 2025: Dr. Vleugels
https://practicaldermatology.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.When Can Atopic Dermatitis Patients Come off Therapy?
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/program-name/57016/Elizabeth (Lisa) Swanson, MD, addresses the common question of how long a pediatric patient may need to be on a medication for atopic dermatitis as opposed to psoriasis.Going Off-Label
https://practicaldermatology.com/conferences/noah-worcester/going-off-label/57063/Francisca Kartono, DO, discusses her presentation, “Practical Pearls: Off-Label Topical and Systemic Strategies that Work,” from the Noah Worcester Dermatological Society’s 2026 Annual Meeting.A Meeting for Treating the Whole Person
https://practicaldermatology.com/conferences/noah-worcester/a-meeting-for-treating-the-whole-person/57065/Stan Tolkachjov, MD, Scientific Program Co-chair for the Noah Worcester Dermatological Society’s 2026 Annual Meeting, explains what he and Co-chair David Wetter, MD, sought to accomplish with this year’s presentations.Commitment to Clinical Evidence in Regenerative Aesthetics
https://practicaldermatology.com/videos/c-suite-chats/commitment-to-clinical-evidence-in-regenerative-aesthetics/54693/Laura Ellis, MD, CEO and Co-Founder of LevEllis, Inc., discusses the current state of aesthetic regenerative medicine and the importance of clinical evidence as the field continues to advance.Advocating for HS Patients
https://practicaldermatology.com/videos/c-suite-chats/advocating-for-hs-patients/54617/Camille Lee, Head of US Immunology at UCB, discusses how her company has worked to elevate the hidradenitis suppurativa (HS) community and what it means to be patient-centric.Considerations for the Use of Biologics in Children with Atopic Dermatitis
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/derm-hub/37152/Dawn Zhang Eichenfield, MD, PhD, a dermatologist at Rady Children's Hospital-San Diego and an assistant clinical professor of dermatology at the University of California, San Diego, School of Medicine, explains the most important factors to understand when prescribing biologics for pediatric atopicA Case Presentation of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37154/Alina Bridges, DO, Director of Dermatopathology & Associate Professor in the Department of Dermatology and Anatomic Pathology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, presents a case study involving a patient who had been on multiple treatments to present prurituDWTV Extra: Phase 3 Data on Roflumilast for AD, PsO
https://practicaldermatology.com/videos/dermwire-tv/dwtv-extra-phase-3-data-on-roflumilast-for-ad-pso/35925/Study investigator Melinda Gooderham, MD, talks about the Phase 3 trials of roflumilast cream 0.15% for adults and children down to age 6 with atopic dermatitis and roflumilast foam 0.3% for patients older than 12 with psoriasis of the scalp and body.The Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.